CSPC Pharmaceutical Group received FDA investigational new drug (IND) clearance for SYH-2082, a long-acting peptide that acts as a GLP-1/GIP dual-biased agonist for weight management in people with obesity or overweight plus comorbidity. The clearance allows CSPC to begin US clinical studies of the injectable candidate. SYH-2082 joins a crowded but high-priority therapeutic area where dual-agonists have driven rapid commercial and clinical activity. IND clearance signals CSPC’s intent to globalize development of its candidate and positions the company to generate US clinical data that could support regulatory filings or partnerships.